Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.85M | -11.53M | -10.22M | -9.83M | -11.12M |
| Total Depreciation and Amortization | 700.00 | 500.00 | 400.00 | 300.00 | 200.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 716.60K | 816.90K | 804.20K | 969.60K | 2.45M |
| Change in Net Operating Assets | -112.40K | -412.50K | 139.30K | 857.70K | 605.20K |
| Cash from Operations | -11.25M | -11.12M | -9.28M | -8.00M | -8.06M |
| Capital Expenditure | -3.20K | -3.20K | -2.80K | -2.80K | -2.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3.20K | -3.20K | -2.80K | -2.80K | -2.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.20K | -3.70K | -2.30K | -900.00 | -- |
| Issuance of Common Stock | 7.76M | 7.21M | 6.28M | 6.28M | 6.35M |
| Repurchase of Common Stock | -24.50K | -54.80K | -103.80K | -101.80K | -83.30K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.73M | 7.16M | 6.18M | 6.18M | 6.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.51M | -3.97M | -3.11M | -1.82M | -1.80M |